3,710 Shares in Astrazeneca Plc $AZN Purchased by Livet Wealth LLC

Livet Wealth LLC purchased a new position in Astrazeneca Plc (NYSE:AZN) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 3,710 shares of the company’s stock, valued at approximately $651,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AZN. Bank of Montreal Can boosted its holdings in shares of Astrazeneca by 344.6% in the 3rd quarter. Bank of Montreal Can now owns 3,478,114 shares of the company’s stock worth $266,841,000 after buying an additional 2,695,793 shares during the last quarter. Holocene Advisors LP boosted its holdings in shares of Astrazeneca by 41.8% in the 3rd quarter. Holocene Advisors LP now owns 6,129,194 shares of the company’s stock worth $470,232,000 after buying an additional 1,807,565 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich boosted its holdings in shares of Astrazeneca by 11,190.9% in the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,806,877 shares of the company’s stock worth $317,107,000 after buying an additional 1,790,874 shares during the last quarter. Raymond James Financial Inc. boosted its holdings in shares of Astrazeneca by 64.8% in the 2nd quarter. Raymond James Financial Inc. now owns 3,783,251 shares of the company’s stock worth $264,373,000 after buying an additional 1,487,662 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Astrazeneca by 4.7% in the 3rd quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock worth $2,503,614,000 after buying an additional 1,461,786 shares during the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on AZN shares. Wall Street Zen raised shares of Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Jefferies Financial Group reissued a “buy” rating on shares of Astrazeneca in a report on Tuesday. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a report on Tuesday. DZ Bank raised shares of Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. Finally, Sanford C. Bernstein reaffirmed a “buy” rating on shares of Astrazeneca in a report on Monday, May 4th. Twelve research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Astrazeneca presently has an average rating of “Moderate Buy” and an average price target of $205.33.

Astrazeneca Price Performance

NYSE AZN opened at $178.79 on Friday. The company has a market cap of $277.28 billion, a PE ratio of 26.85, a price-to-earnings-growth ratio of 1.59 and a beta of 0.25. Astrazeneca Plc has a 52 week low of $137.23 and a 52 week high of $212.71. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. The firm’s 50-day simple moving average is $189.26 and its two-hundred day simple moving average is $185.90.

Astrazeneca (NYSE:AZN) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.52 by $0.06. The business had revenue of $15.29 billion for the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. Research analysts predict that Astrazeneca Plc will post 9.37 earnings per share for the current year.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.